PAR 2.17% 23.5¢ paradigm biopharmaceuticals limited..

Community Adoption / Mr Federer, page-70

  1. 9,810 Posts.
    lightbulb Created with Sketch. 1243
    Wow I can't believe most haven't picked up on the fact that MM is just taking the piss here:

    ".....if you look at the data behind it, you'll find that the change (volume) wasn't significant in a stastistical sense. nice picture but nothing conclusive. A number of studies suggest BMLs heal by themselves without treatment so having a time lapse with a reduction on BML isnt convincing"

    If you look at the MRI data released to date it has the potential to see higher statistical significance than the already clinically significant pain and function primary end points.

    The MRI data showed large reductions in BML Grade, Volume and Area that signals potential of disease regression of osteoarthritis in subjects treated with iPPS.


    • iPPS treatment reduced BML Volume by (-)37.3% in contrast to an increase of (+)28.5% in the placebo.
    • iPPS treatment reduced BML Area by (-)15.6% in contrast to an increase of (+)15.2%, in the placebo group.

    By iPPS achieving a regression in BML, according the peer reviewed scientific literature, there is strong evidence to show iPPS is treating the root causes of the OA pain, cartilage degradation and joint degeneration
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.5¢
Change
0.005(2.17%)
Mkt cap ! $82.20M
Open High Low Value Volume
23.0¢ 25.0¢ 23.0¢ $211.2K 895.4K

Buyers (Bids)

No. Vol. Price($)
4 82174 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.5¢ 49300 8
View Market Depth
Last trade - 16.10pm 06/08/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.